Drug Profile
Bevacizumab biosimilar - Reliance Life Sciences
Alternative Names: R TPR 023Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer
Most Recent Events
- 19 Feb 2016 Bevacizumab biosimilar is still in phase III trial for Colorectal cancer (Metastatic disease, First-line therapy) in India (IV) (CTRI2013-05-003699)
- 28 May 2013 Phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy) in India (IV)